Table.
aTZP-102 is under evaluation in a 12-week, phase 2b trial; bThis result has come from a 4-week double-blind, placebo-controlled study.
aTZP-102 is under evaluation in a 12-week, phase 2b trial; bThis result has come from a 4-week double-blind, placebo-controlled study.